Logo image of GDTC

CYTOMED THERAPEUTICS LTD (GDTC) Stock Fundamental Analysis

NASDAQ:GDTC - SGXZ17669631 - Common Stock

2.01 USD
+0.04 (+2.03%)
Last: 8/27/2025, 11:06:29 AM
Fundamental Rating

3

GDTC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 547 industry peers in the Biotechnology industry. GDTC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GDTC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GDTC had negative earnings in the past year.
GDTC had a negative operating cash flow in the past year.
In the past 5 years GDTC always reported negative net income.
GDTC had a negative operating cash flow in each of the past 5 years.
GDTC Yearly Net Income VS EBIT VS OCF VS FCFGDTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -1M -2M -3M -4M

1.2 Ratios

Looking at the Return On Assets, with a value of -28.08%, GDTC is in the better half of the industry, outperforming 69.65% of the companies in the same industry.
GDTC has a better Return On Equity (-30.14%) than 77.33% of its industry peers.
Industry RankSector Rank
ROA -28.08%
ROE -30.14%
ROIC N/A
ROA(3y)-42.33%
ROA(5y)-41.37%
ROE(3y)-215.47%
ROE(5y)-218.97%
ROIC(3y)N/A
ROIC(5y)N/A
GDTC Yearly ROA, ROE, ROICGDTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

1.3 Margins

GDTC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GDTC Yearly Profit, Operating, Gross MarginsGDTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, GDTC has about the same amount of shares outstanding.
Compared to 1 year ago, GDTC has an improved debt to assets ratio.
GDTC Yearly Shares OutstandingGDTC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
GDTC Yearly Total Debt VS Total AssetsGDTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

An Altman-Z score of 21.44 indicates that GDTC is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 21.44, GDTC belongs to the top of the industry, outperforming 93.60% of the companies in the same industry.
A Debt/Equity ratio of 0.04 indicates that GDTC is not too dependend on debt financing.
GDTC's Debt to Equity ratio of 0.04 is in line compared to the rest of the industry. GDTC outperforms 40.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 21.44
ROIC/WACCN/A
WACCN/A
GDTC Yearly LT Debt VS Equity VS FCFGDTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M 10M

2.3 Liquidity

A Current Ratio of 21.54 indicates that GDTC has no problem at all paying its short term obligations.
GDTC has a better Current ratio (21.54) than 95.06% of its industry peers.
A Quick Ratio of 21.54 indicates that GDTC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 21.54, GDTC belongs to the top of the industry, outperforming 95.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 21.54
Quick Ratio 21.54
GDTC Yearly Current Assets VS Current LiabilitesGDTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

GDTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.91%, which is quite impressive.
EPS 1Y (TTM)59.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GDTC will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.02% on average per year.
Based on estimates for the next years, GDTC will show a quite strong growth in Revenue. The Revenue will grow by 9.59% on average per year.
EPS Next Y42.31%
EPS Next 2Y16.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year31.87%
Revenue Next 2Y9.59%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

GDTC Yearly Revenue VS EstimatesGDTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 100K 200K 300K 400K 500K
GDTC Yearly EPS VS EstimatesGDTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 -0.05 -0.1 -0.15 -0.2 -0.25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GDTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GDTC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GDTC Price Earnings VS Forward Price EarningsGDTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GDTC Per share dataGDTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as GDTC's earnings are expected to grow with 16.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.02%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

GDTC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOMED THERAPEUTICS LTD

NASDAQ:GDTC (8/27/2025, 11:06:29 AM)

2.01

+0.04 (+2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05
Earnings (Next)09-30 2025-09-30
Inst Owners0.32%
Inst Owner ChangeN/A
Ins Owners12.77%
Ins Owner Change0%
Market Cap23.20M
Analysts82.86
Price Target5.1 (153.73%)
Short Float %1.08%
Short Ratio3.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.93
P/tB 2.94
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0
BVpS0.69
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.08%
ROE -30.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.33%
ROA(5y)-41.37%
ROE(3y)-215.47%
ROE(5y)-218.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 275.74%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.54
Quick Ratio 21.54
Altman-Z 21.44
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)103.86%
Cap/Depr(5y)210.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.52%
EPS Next Y42.31%
EPS Next 2Y16.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year31.87%
Revenue Next 2Y9.59%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.78%
OCF growth 3YN/A
OCF growth 5YN/A